anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Current guidelines emphasize the diagnostic value of non-cardiac or possibly cardiac chest pain. The goal of this analysis was to determine whether German chest pain units (CPUs) adequately address conditions with "atypical" chest pain in existing diagnostic structures.
METHOD: A total of 11,734 patients from the German CPU registry were included. The analyses included mode of admission, critical time intervals, diagnostic steps, and differential diagnoses.
RESULTS: Patients with unspecified chest pain were younger, more often female, were less likely to have classic cardiovascular risk factors and tended to present more often as self-referrals. Patients with acute coronary syndrome (ACS) mostly had prehospital medical contact. Overall, there was no difference between these two groups regarding the time from the onset of first symptoms to arrival at the CPU. In the CPU, the usual basic diagnostic measures were performed irrespective of ACS as the primary working diagnosis. In the non-ACS group, further ischemia-specific diagnostics were rarely performed. Extra-cardiac differential diagnoses were not specified.
CONCLUSION: The establishment of broader awareness programs and opening CPUs for low-threshold evaluation of self-referring patients should be discussed. Regarding the rigid focus on the clarification of cardiac causes of chest pain, a stronger interdisciplinary approach should be promoted.
Tisotumab vedotin-tftv is a tissue factor (TF)-directed antibody drug conjugate (ADC). The antibody is a human IgG1 directed against cell surface TF. TF is the primary initiator of the extrinsic blood coagulation cascade. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease-cleavable linker. Nonclinical data suggests that the anticancer activity of tisotumab vedotin-tftv is due to the binding of the ADC to TF expressing cancer cells, followed by internalization of the ADC-TF complex, and release of MMAE via proteolytic cleavage. MMAE disrupts the microtubule network of actively dividing cells, leading to cell cycle arrest and apoptotic cell death. In vitro, tisotumab vedotin-tftv also mediates antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity.
Group 1 will receive a standard ureteral stent. Diameter: 6F, length according to surgeons' estimation and patient's height.
Olvi-Vec (olvimulogene nanivacirepvec, aka GL-ONC1, laboratory name: GLV-1h68) is an oncolytic vaccinia virus-based immunotherapy. This study is to test the hypothesis that the combination of Olvi-Vec followed by further chemotherapy is particularly effective against established tumors by virus-mediated immune activation and re-sensitization of tumor cells to chemotherapy. Participant population includes histologically confirmed non-resectable platinum-resistant/refractory ovarian cancer (PRROC). Determination of progression-free survival, safety and overall survival are key objectives. Participants randomized into the Experimental Arm will receive a single-cycle (2 infusions on two consecutive days) of Olvi-Vec through an intraperitoneal catheter. The catheter is then removed, and patients receive systemically administered platinum-doublet chemotherapy and bevacizumab. The control arm receives the Physician's Choice of chemotherapy and bevacizumab at the same dose and schedule. Biological samples will be obtained from some Experimental Arm participants for virus-shedding testing. Assessment of response to treatment in both arms will be by RECIST 1.1 and iRECIST as assessed by Blinded Independent Central Review. Maintenance/continued treatment with non-platinum chemotherapy and bevacizumab is dependent on a participant being clinically stable until confirmed progressive disease by iRECIST or can no longer tolerate therapy.

Dr. Robert W. Holloway (AdventHealth Cancer Institute, Orlando, FL) will serve as the National Principal Investigator for this Phase 3 study in PRROC.
Kenalog®-10 Injection (triamcinolone acetonide injectable suspension, USP) is triamcinolone acetonide, a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. THIS FORMULATION IS SUITABLE FOR INTRA-ARTICULAR AND INTRALESIONAL USE ONLY.

Each mL of the sterile aqueous suspension provides 10 mg triamcinolone acetonide, with 0.66% sodium chloride for isotonicity, 0.99% (w/v) benzyl alcohol as a preservative, 0.63% carboxymethylcellulose sodium, and 0.04% polysorbate 80. Sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.

The chemical name for triamcinolone acetonide is 9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. Its structural formula is:

MW 434.50
The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Patients will then under regular gastric cancer resection with D2 lymphadenectomy as per routine in our institution.
This is a two-arm non-randomized convenient pilot trial to assess impact of an active glycemic management model through remote glucose monitoring technology amongst patients with DFUWI and poor glycemic control at the Parkland Diabetes Foot \& Wound clinic. The plan is to implement a remote glucose monitoring technology to facilitate improved glycemic management and control. A cellular enabled glucose meter that will upload blood glucose measurements to a cloud server accessible by providers who can remotely review glycemic trends and remotely provide patients with proactive recommendations for treatment adjustments will be used. Patients receiving services in the integrated care model (same day visits in the Foot Wound and Diabetes Clinics at Parkland) will be eligible for inclusion in the intervention arm which includes proactive glucose monitoring guided by remote glucose monitoring technology. Patients receiving usual care services (non-integrated care model clinic days where Foot Wound and Diabetes Clinic visits are on separate days) will be eligible for inclusion in the control arm. The expectation is that patients in the intervention arm will experience greater improvements in glycemic control, compared to the usual care model. The hypothesis is that improved glycemic control in these patients will result in faster healing of diabetic foot wound, infections or ulcers. The effectiveness of the technologically facilitated integrated model of care will be evaluated compared to the usual care using metrics for diabetic foot ulcers and wound healing, glycemic control, patient reported outcomes, health resource utilization and medication adherence after 6 months of intervention. The Telcare 2.0 BGM for remote self-blood glucose monitoring(FDA Cleared) will be used.
A portable, self-contained, microprocessor controlled apparatus for monitoring, storing and transmitting detected physiological information, including means for sequentially receiving analog signals corresponding to heart activity for as many as twelve different cardiac sensors. Means are provided for receiving analog electrical signals corresponding to blood pressure from at least one sensor. Means are providing for converting the received analog signals to a series of digital pulses at a predetermined sampling rate and for receiving and storing the digital pulses in predetermined memory locations. Means are provided for recalling the stored digital pulses from the memory means and for receiving the recalled digital pulses and for transmitting them to a remote location over a communications system. In the preferred embodiment, means are provided for receiving analog signals corresponding to cardiac conductivity, brainwave activity, blood pressure, blood flow and other ultrasonic cardiovascular and intracranial data. The latter signals are also converted to digital form for storage and later recall and transmission to a remote location.
The invention discloses a medicinal tea for protecting liver. The medicinal tea is bagged medicinal tea, which comprises the following herbs in proportion by weight: 10-12 mulberry leaf, 15-18 mulberry twig, 7-10 lophatherum gracile, 7-10 vine of multiflower knotweed, 6-8 epimedium and 10-15 semen cassiae. The herbs are selected, dried, smashed and evenly mixed according to the proportion by weight to get mixed medicinal powder, and then packed in bags according to the conventional tea bag manufacturing technique. The medicinal tea is taken after soaked in hot water for 3 times a day, each time a bag of the medicinal tea is soaked in 200 ml boiled water, each bag of the medicinal tea can be used for 3-4 times repeatedly, and a patient can drink the medical tea as water. The medicinal tea for protecting liver provided by the invention is made of natural Chinese medicinal materials and can effectively alleviate pain symptoms in the liver region. The medicinal tea has an obvious effect for protecting liver, can be used for preventing and treating acute hepatitis, chronic hepatitis and viral hepatitis, and is suitable for people with liver diseases.
The present invention generally relates to a process suitable for extracorporeal lung support. The process relies on exposing blood, separated by a semipermeable membrane from the dialysis liquid. The dialysis liquid of the present invention comprises a buffering agent and has a high buffering capacity for H +  ions. Carbon dioxide, bicarbonate and hydrogen cations can be efficiently transported across a semipermeable membrane to the dialysis liquid. The present invention also allows for the regeneration and recycling of the dialysis liquid, and thus for its recycling and repeated use. The versatility of the dialysis liquid allows to adjust the pH of the dialysis liquid, add fluids to the dialysis liquid and/or to the blood in the extracorporeal circuit and to remove substances from the blood in the extracorporeal circuit, depending on the conditions and needs. Thus, the present invention is versatile, and suitable for treating or preventing respiratory acidosis, metabolic acidosis, diseases associated with lung malfunction and/or kidney malfunction and/or liver malfunction. For example, when the kidney function is limited, the acid-base balance of the blood can be provided by the method of the present invention; and when the liver function is limited, toxins can be removed from blood by the method of the present invention.
BACKGROUND: As a biomarker of alveolar-capillary basement membrane injury, Krebs von den Lungen-6 (KL-6) is involved in the occurrence and development of pulmonary diseases. However, the role of the KL-6 in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) has yet to be elucidated. This prospective study was designed to clarify the associations of the serum KL-6 with the severity and prognosis in patients with AECOPD.
METHODS: This study enrolled 199 eligible AECOPD patients. Demographic data and clinical characteristics were recorded. Follow-up was tracked to evaluate acute exacerbation and death. The serum KL-6 concentration was measured via an enzyme-linked immunosorbent assay.
RESULTS: Serum KL-6 level at admission was higher in AECOPD patients than in control subjects. The serum KL-6 concentration gradually elevated with increasing severity of AECOPD. Pearson and Spearman analyses revealed that the serum KL-6 concentration was positively correlated with the severity score, monocyte count and concentrations of C-reactive protein, interleukin-6, uric acid, and lactate dehydrogenase in AECOPD patients during hospitalization. A statistical analysis of long-term follow-up data showed that elevated KL-6 level at admission was associated with longer hospital stays, an increased risk of future frequent acute exacerbations, and increased severity of exacerbation in COPD patients.
CONCLUSION: Serum KL-6 level at admission is positively correlated with increased disease severity, prolonged hospital stay and increased risk of future acute exacerbations in COPD patients. There are positive dose-response associations of elevated serum KL-6 with severity and poor prognosis in COPD patients. The serum KL-6 concentration could be a novel diagnostic and prognostic biomarker in AECOPD patients.
Growth disorders resulting in extreme short stature (ESS) are often a result of deficiency in growth hormone (GH) released from the pituitary gland or a defective GH releasing receptor. Genetic defects in the GH1 and GHRHR genes account for around 11.1-20% of ESS cases, resulting in a rare condition called isolated GH deficiency (IGHD). We describe the characterization of a GH1 genetic defect discovered in a 3-year-old male patient with ESS, developmental failure and undetectable serum levels of GH. There was a family history of short stature, with both parents being short. Whole genome sequencing of the patient DNA revealed a large, novel 6 kb homozygous deletion spanning the entire GH1 gene in the patient. While the deletion was homozygous in the proband, it was present in the heterozygous state in the parents. Thus, we report a novel homozygous deletion including the GH1 gene leading to IGHD-type 1A associated with ESS.
The invention discloses a preparation method and application of platinum-zinc oxide heterojunction nanoparticles. Takes zinc acetate as a precursor and sodium hydroxide as a pH regulator to synthesize Zn (OH)  2  Then dehydrating in a methanol system to synthesize ZnO. And then, taking ZnO as a template and sodium borohydride as a reducing agent, and synthesizing the Pt-ZnO nano particles by reducing chloroplatinic acid in situ. The invention can control the size and the shape of the Pt-ZnO by adjusting the concentration of NaOH, the volume ratio of water to methanol and the reduction time, and the prepared Pt-ZnO hydrated particle size is about 160nm. The method has simple operation, short time consumption and mild synthesis conditionsControllable and has strong reproducibility. Under ultrasound, pt-ZnO can show the characteristics of a sonosensitizer and generate a large amount of singlet oxygen: (  1  O  2  ). And Pt-ZnO has peroxidase-like and catalase-like dual nanoenzyme activities and can catalyze hydrogen peroxide to generate hydroxyl radicals (. OH) and oxygen.
Patients with severe burns are at high risk of thermoregulatory failure. Yet, there is a lack of consensus regarding the optimum approach to temperature dysregulation in patients with severe burns. Intravascular temperature management catheters may offer a superior method of temperature control, but robust data are lacking. In this article, we describe our experience in using a thermoregulatory catheter for temperature management in a tertiary referral burns center. We conducted a single-center, prospective evaluation of the use of a thermoregulatory intravenous catheter system (Thermogard XP®) in critically injured burns patients admitted to our intensive care unit over an 18-month period. Ten patients had a total of 12 catheters inserted. Patient temperatures were maintained between a median low of 36.9 °C and a median high of 38.4 °C while in the intensive care unit. If patients were transferred to theater, the median temperature change was -0.15 °C (interquartile range [IQR] -0.3, 0) if TBSA was ≤50% and -1.45 °C (IQR -2.05, -0.975) if >50%. No surgical procedures were terminated due to intraoperative hypothermia. On return from theater, 72.2% of patients were normothermic with a median temperature of 36.8 °C. Thirty percent of patients developed a thrombotic complication. Overall, the device appeared reliable in achieving and maintaining normothermia for critically ill burns patients manifesting temperature dysregulation. It may also be of benefit to patients expected to show temperature fluctuations during operative procedures. Further research is needed to define whether this represents an improvement over current practice and investigate the thrombus risk associated with such devices.
PURPOSE: To investigate how passive hyperthermia affect the resting-state functional brain activity based on an acute mouse model after heat stress exposure.
MATERIALS AND METHODS: Twenty-eight rs-fMRI data of C57BL/6J male mice which weighing about 24 ∼ 29 g and aged 12 ∼ 16 weeks were collected. The mice in the hyperthermia group (HT, 40 °C ± 0.5 °C, 40 min) were subjected to passive hyperthermia before the anesthesia preparation for scanning. While the normal control group (NC) was subjected to normothermia condition (NC, 20 °C ± 2 °C, 40 min). After data preprocessing, we performed independent component analysis (ICA) and region of interested (ROI)-ROI functional connectivity (FC) analyses on the data of both HT (n = 13) and NC (n = 15).
RESULTS: The group ICA analysis showed that the HT and the NC both included 11 intrinsic connectivity networks (ICNs), and can be divided into four types of networks: the cortical network (CN), the subcortical network (SN), the default mode network (DMN), and cerebellar networks. CN and SN belongs to sensorimotor network. Compared with NC, the functional network organization of ICNs in the HT was altered and the overall functional intensity was decreased. Furthermore, 13 ROIs were selected in CN, SN, and DMN for further ROI-ROI FC analysis. The ROI-ROI FC analysis showed that passive hyperthermia exposure significantly reduced the FC strength in the overall brain represented by CN, SN, DMN of mice.
CONCLUSION: Prolonged exposure to high temperature has a greater impact on the overall perception and cognitive level of mice, which might help understand the relationship between neuronal activities and physiological thermal sensation and regulation as well as behavioral changes.
The study is Randomized controlled trial. The study will be conducted on 44 stroke patients. The study will be conducted in Civil Hospital Shujaabad and Riphah rehabilitation centre Lahore. Patients will be divided into Group A (n = 20) and Group B (n = 20) using a randomization through computer generated numbers program. Patients in Group A will receive action observation training with conventional treatment. All participants will undergo the training for 25 minutes per session, 5 days per week for 8 weeks. Patients in Group B will receive motor imagery with conventional treatment. All participants will receive interventions for twenty-five minutes per session, five times a week, for eight weeks. For the pre- and post-evaluation of all participants, Fugl-Meyer Assessment Upper Extremity (FMA UE) and Wolf Motor Function Test (WMFT) will be used. Data will be analyzed by using SPSS (Statistical package for Social Sciences) 25 version.
The investigators will recruit n=30 patients with stage I-III colorectal cancer and randomize them to a 12-week resistance training intervention with Theraband and existing evidence- based materials or attention control using a meditation intervention. Using an electronic survey tool, patients will complete a baseline questionnaire on key outcomes (quality of life, fatigue, side effects) and potential confounders and will consent to a medical record review. These will also be assessed via at 4 weeks post randomization and 12 weeks post randomization. Participants in the intervention group will receive one-time in person instruction in the exercises derived from the existing evidence base of home-based resistance training programs for older adults and cancer survivors. They will be sent home with a book demonstrating the exercises, a log and a set of appropriate resistance bands. Weekly follow-up calls will occur for the duration of the intervention and updates on the call results will be provided to the colon cancer clinic nurse so that care is integrated. Participants in the attention control group will be mailed a meditation CD. Follow-up in the control group will parallel that of the intervention group, with weekly calls.
PURPOSE: A composition for prevention and treatment of periodontal disease containing a titrated extract of the unsaponifiable fraction of Zea mays L. and a Magnolia officinalis extract as a main component is provided, which has a synergistic anti-inflammatory activity. CONSTITUTION: This composition contains a titrated extract of the unsaponifiable fraction of Zea mays L. and a Magnolia officinalis extract in a weight ratio of 0.5:1 to 1.0:1. The formulation of the composition is selected from tablet, ointment or spray. For an example, 1Kg corn oil extracted from maize germ is extracted with 10L n-hexane and 0.68L caustic soda to produce a titrated extract of the unsaponifiable fraction. And 500g Magnolia officinalis or Magnolia obovata Thunb. is extracted in 3L ethanol and mixed with the titrated extract of the unsaponifiable fraction of Zea mays L. in a weight ratio of 1:0.5, 1:1.0, 1:1.5, 1:2.0.
Cohort 4: 800 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 3 by a Safety Review Committee.
Estrogenic compositions comprising calycosin and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.
PURPOSE:To obtain a substance having antitumor action, by aerobically cultivating a strain belonging to the genus Streptomyces, capable of producing K3619. CONSTITUTION:Strain K3619 belonging to the genus Streptomyces having mycologic properties of shape: cylindrical egg-shaped and size of 0.6-0.8X0.8-1.0mum; growth: poor in glucose medium; hydrolysis of starch: negative by 20-30 deg.C culture; using D-glucose and not assimilating D-fructose; etc. is obtained by separation operation of soil collected in Brazil. Then the strain K3619 is cultivated by aerated culture in a medium containing glucose, yeast essence, NaCl, etc. at 20-37 deg.C for about 5 days to give a culture mixture. Then the culture mixture is extracted and purified to recover a substance, a compound shown by the formula. Optionally an antitumor agent comprising the compound as an active ingredient is prepared.